« Previous
Next »
Fertility and Sterility
Volume 91, Issue 4,
Supplement
, Pages 1303-1306
, April 2009
Cyclooxygenase-2 overexpression in ovarian endometriomas is associated with higher risk of recurrence
References
- . The effectiveness of laparoscopic excision of endometriosis. Curr Opin Obstet Gynecol. 2004;16:299–303
- . Management of recurrent endometriosis. In: Couinho E, Spinola P, DeMoura LH editor. Progress in the management of endometriosis. London: Partheon; 1995;p. 291–297
- . The current staging system for endometriosis: does it help?. Obstet Gynecol Clin North Am. 2003;30:115–132
- Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 2005;57:359–383
- . Nuclear factor-kappaB (NF-kappaB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large?. Gynecol Obstet Invest. 2006;63:71–97
- . Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod. 2001;16:561–566
- Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol. 2002;48:50–56
- . Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertil Steril. 2004;82:1309–1315
- . COX-2 overexpression in peritoneal lesions is correlated with nonmenstrual chronic pelvic pain. Eur J Obstet Gynecol Reprod Biol. 2006;124:216–221
- . Cyclooxygenase-2 regulates survival, migration and invasion of human endometriotic cells through multiple mechanisms. Endocrinology. 2008;149:1180–1189
- . Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril. 2004;82:1609–1615
- . A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertil Steril. 2006;86(Suppl 4):1146–1151
- . Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril. 2007;87:163–171
- The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol. 2004;116:100–102
- Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters. Hum Reprod. 2004;19:393–397
- Increased cyclooxygenase-2 expression is associated with better clinical outcome in patients submitted to complete ablation for severe endometriosis. Hum Reprod. 2005;20:2964–2968
- Staging of pelvic endometriosis: role of sonographic appearance in determining extension of disease and modulating surgical approach. J Am Assoc Gynecol Laparosc. 2003;10:378–382
- . R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5:1923–1927
- Distinct mechanisms regulate cyclooxygenase-1 and -2 in peritoneal macrophages of women with and without endometriosis. Mol Hum Reprod. 2002;8:1103–1110
- . IL-1 beta, TNF-alpha, and IL-2 in peritoneal fluid and macrophage-conditioned media of women with endometriosis. Am J Reprod Immunol. 1995;34:381–385
- IL-1, IL-6 and TNF-alpha concentrations in the peritoneal fluid of women with pelvic adhesions. Hum Reprod. 2002;17:69–75
- . Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab. 2005;90:286–295
- . Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
- . Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94:3336–3340
- . Invasiveness of endometriotic cells in vitro. Lancet. 1995;346:1463–1464
- . Suppression of IL-1beta-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol. 2007;135:88–93
L.Y. has nothing to disclose. F.S. has nothing to disclose. Y.L. has nothing to disclose. X.L. has nothing to disclose. S.-W.G. has nothing to disclose.
L.Y. and F.S. contributed equally to this work.
PII: S0015-0282(08)00164-7
doi: 10.1016/j.fertnstert.2008.01.070
© 2009 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Fertility and Sterility
Volume 91, Issue 4,
Supplement
, Pages 1303-1306
, April 2009

